Introduction {#sec1-1}
============

Heart failure (HF) is a global, epidemic clinical syndrome with millions of affected people ([@ref1]). Recent guidelines separate patients with HF to either reduced ejection fraction (HFrEF) (\<40%), mid-range ejection fraction (HFmrEF) (40%-49%), and preserved ejection fraction (HFpEF) (\>50%) ([@ref2]). Nearly half of the worldwide population with HF has either HFpEF or HFmrEF ([@ref3], [@ref4]). This condition is a major public health problem because its prevalence increases at an alarming rate of 1% per year ([@ref5]), with rates of cardiovascular events that are similar to those seen in HFrEF ([@ref6], [@ref7]). Despite the fact that more than half of the patients with HF in routine care are women, randomized clinical trials supporting current HF management guidelines have recruited predominantly male subjects with a lack of prospective gender-specific analyses ([@ref8]). Some evidence, largely from registries, reveal important gender differences in HF etiology, risk factors, and clinical characteristics: women, compared with men, tend to be older, with non-ischemic HF etiology, and higher blood pressure, as well as more comorbidities such as renal failure and diabetes mellitus ([@ref9]). Also, recent studies suggest that female patients with HFpEF show distinct characteristics and outcomes compared with men ([@ref10]). Risk factors for development of HFpEF include renal failure, hypertension, and obesity in women, and ischemic heart disease, chronic obstructive pulmonary disease, and atrial fibrillation in men ([@ref11], [@ref12]).

HFmrEF is a new category of HF. Recent studies revealed that patients with HFmrEF represent a demographically and clinically diverse group with many intermediate features compared with HFrEF and HFpEF ([@ref13]). According to the available data, patients with HFmrEF are younger and more predominantly male compared with those with HFpEF ([@ref14]). However, data of gender-related differences in clinical characteristics and management are limited in patients with HFmrEF, and most of the available data on gender-based characteristics in such patients are obtained from developed countries. Therefore, we performed a post-hoc analysis of data from the APOLLON trial (A comPrehensive, ObservationaL registry of heart faiLure with mid-range and preserved ejection fractiON) to explore the gender-related differences in demographic characteristics, clinical profile, and management of patients with HFpEF and HFmrEF.

Methods {#sec1-2}
=======

The APOLLON registry {#sec2-1}
--------------------

Design and results of the original study have been described elsewhere ([@ref15], [@ref16]). Briefly, the APOLLON study is a multicenter and observational study conducted in Turkey (ClinicalTrials.gov identifier NCT03026114), in which patients with HFmrEF and HFpEF aged ≥18 years were enrolled in the study between March 31, 2018, and May 20, 2018. A total of 1065 patients who presented to the outpatient cardiology clinics with sign and/or symptoms of HF were enrolled in the study at 11 sites across the country (total 13 hospitals in 11 cities; 6 university hospitals, 4 training and research hospitals, and 3 secondary hospitals). All information, such as demographic characteristics, medical history, laboratory data, electrocardiography, and echocardiography data, were recorded at the time of enrollment.

Patients with a left ventricular ejection fraction (LVEF) ≥40% and N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels \>125 pg/mL, and patients with signs and/or symptoms of HF were included in this study. One symptom must be present at the time of screening, and one sign must have been present in the last 12 months. To determine HFpEF and HFmrEF, at least one additional echocardiographic criterion including relevant structural heart disease or diastolic dysfunction was required. Key structural alterations were accepted as a left atrial volume index (LAVI) \>34 mL/m^2^ or a left ventricular mass index (LVMI) ≥115 g/m^2^ for males and ≥95 g/m^2^ for females. Key diastolic dysfunction criteria were accepted an E/e′ ≥13 and a mean e' septal and lateral wall \<9 cm/s.

Patients with an LVEF \<40%; patients with significant chronic pulmonary disease; patients with primary severe heart valve disease requiring intervention or surgery; patients with any history of surgically corrected heart valve diseases (e.g., mechanical or bioprosthetic heart valves); patients with myocardial infarction, stroke, or coronary artery bypass graft surgery in the past 90 days; percutaneous coronary intervention or pacemaker implantation in the past 30 days; heart transplant recipients; known infiltrative or hypertrophic obstructive cardiomyopathy or known pericardial constriction; patients with congenital heart diseases or cor pulmonale; and pregnant patients were excluded from the study.

The APOLLON study was approved by the Local Ethics Committee, and informed consent was obtained from all patients.

Study design {#sec2-2}
------------

Among the 1065 (mean age of 67.1±10.6 years) patients, 577 (54.2%) were female, and 488 (45.8%) were male. Using the registry data of these patients, we examined gender differences in terms of clinical characteristics and management of patients with HFmrEF and HFpEF.

Statistical analyses {#sec2-3}
--------------------

Baseline continuous variables are presented as mean ± standard deviations or median, first quartile (Q1) and third quartile (Q3); depending on the distribution of the data. The categorical variables are expressed in frequencies and percentages. The Pearson's Chi-square test was used to compare categorical variables. The continuous variables were compared using the t-test or the Mann--Whitney U-test, as appropriate. Clinical characteristics of female and male patients were compared using Fisher's exact test with two-sided p-values. Analyses were performed with the statistical package SPSS 24.0 (SPSS Inc, Chicago, Illinois, USA).

Results {#sec1-3}
=======

The baseline characteristics of the patients are listed in [Table 1](#T1){ref-type="table"}. Compared with men, women with HFpEF and HFmrEF were older; and they more frequently had palpitation, peripheral edema, fatigue, and reduced exercise tolerance. Female participants had higher body mass index and heart rate when compared with what their male counterparts had. Women had higher prevalence of hypertension and atrial fibrillation. However, men had higher prevalence of coronary and peripheral artery disease, and hyperlipidemia. There were significantly fewer smokers and alcohol users among the women. The ratio of patients with HFpEF was significantly higher in females than in males, but the ratio of HFmrEF was more common in men than that in women. Of the 577 female, 104 (18%) had HFmrEF; whereas of the 488 male, 142 (29.1%) had HFmrEF (p\<0.001). Of the 577 female, 473 patients had HFpEF (82%), but of the 488 male, 346 (70.9%) had HFpEF (p\<0.001).

###### 

Patient demographics, characteristics, and comorbid features for all population

                                                       Female (n=577)   Male (n=488)     *P* value
  ---------------------------------------------------- ---------------- ---------------- -----------
  Age, years                                           68 (61--76)      67 (60--74)      \<0.001
  Smoking                                              32 (5.5)         156 (32.0)       \<0.001
  Alcohol use                                          5 (0.9)          41 (8.4)         \<0.001
  Paroxysmal nocturnal dyspnea                         217 (37.6)       150 (30.7)       0.082
  Palpitation                                          326 (56.5)       176 (36.1)       \<0.001
  Reduced exercise tolerance                           499 (86.5)       380 (77.9)       \<0.001
  Fatigue, tiredness                                   399 (69.2)       279 (57.2)       \<0.001
  Chest pain                                           141 (24.4)       133 (27.3)       0.295
  Syncope                                              29 (5.0)         16 (3.3)         0.158
  Dizziness                                            123 (21.3)       87 (17.8)        0.154
  Body mass index, kg/m^2^                             29 (26--33)      27 (25--30)      \<0.001
  Systolic blood pressure, mm Hg                       130 (120--145)   130 (120--145)   0.539
  Diastolic blood pressure, mm Hg                      80 (70--90)      80 (70--85)      0.848
  Heart rate, bpm                                      80 (71.5--94)    77.5 (69--89)    \<0.001
  Pulmonary crepitations                               138 (23.9)       97 (19.9)        0.113
  Peripheral edema                                     220 (38.1)       136 (27.9)       \<0.001
  ECG abnormality                                      323 (56.0)       293 (60.0)       0.181
  Cachexia                                             24 (4.2)         11 (2.3)         0.082
  History of hospitalization for HF in the last year   123 (21.3)       98 (20.1)        0.620
  **Comorbidities**                                                                      
   Atrial fibrillation                                 235 (40.7)       146 (29.9)       \<0.001
   Hypertension                                        454 (78.7)       357 (73.2)       0.035
   Diabetes mellitus                                   184 (31.9)       135 (27.7)       0.134
   Anemia                                              204 (35.3)       168 (34.4)       0.486
   Chronic kidney disease                              59 (10.2)        73 (15.0)        0.19
   Obstructive sleep apnea                             30 (5.2)         31 (6.4)         0.420
   Hyperlipidemia                                      120 (20.8)       144 (29.5)       0.001
   Coronary artery disease                             170 (29.5)       268 (54.9)       \<0.001
   Previous myocardial infarction                      69 (12.0)        128 (26.2)       \<0.001
   Coronary artery by-pass grafting                    57 (9.9)         98 (20.1)        \<0.001
   Peripheral artery disease                           7 (1.2)          21 (4.3)         0.002
   CVA/TIA                                             39 (6.8)         31 (6.4)         0.790
   COPD                                                71 (12.3)        72 (14.8)        0.243
   Hepatic failure                                     11 (1.9)         7 (1.4)          0.552
   Depression                                          41 (7.1)         17 (3.5)         0.009
   Malignancy                                          5 (0.9)          14 (2.9)         0.014
  Heart failure with mid-range ejection fraction       104 (18.0)       142 (29.1)       \<0.001
  Heart failure with preserved ejection fraction       473 (82.0)       346 (70.9)       

COPD - chronic obstructive pulmonary disease; CVA - cerebrovascular accident; HF - heart failure; TIA - transient ischemic attack

Tables [2](#T2){ref-type="table"} and [3](#T3){ref-type="table"} show the comparison of laboratory parameter and echocardiographic findings according to the gender. The NT-proBNP levels were significantly higher in women (691 pg/mL vs. 541 pg/mL, p=0.004), but hemoglobin and ferritin levels were significantly lower in women than those in men.

###### 

Laboratory parameters

                                 Female (n=577)      Male (n=488)        *P* value
  ------------------------------ ------------------- ------------------- -----------
  NT-proBNP, pg/mL               691 (285--1323)     541 (259--918)      0.004
  Fasting blood glucose, mg/dL   105 (94--133)       106 (93--123)       0.326
  Blood urea nitrogen, mg/dL     17 (13--24)         17 (14--22)         0.766
  Serum creatinine, mg/dL        0.8 (0.7--1.0)      0.9 (0.8--1.1)      \<0.001
  Serum sodium, mmol/L           141 (139--143)      141 (139--143)      0.874
  Serum potassium, mmol/L        4.6 (4.3--4.9)      4.6 (4.2--4.9)      0.334
  Serum calcium, mg/dL           9.3 (8.9--9.7)      9.3 (8.9--9.7)      0.816
  Uric acid, mg/dL               5.5 (4.5--6.8)      5.7 (4.9--6.9)      0.016
  Hemoglobin, g/dL               12.7 (11.4--13.6)   13.8 (12.4--15.0)   \<0.001
  Leukocyte, x10^3^/µL           7.8 (6.5--9.2)      7.9 (6.7--9.4)      0.538
  C-reactive protein, mg/dL      3.5 (1.8--7.9)      3.2 (1.9--7.0)      0.095
  Ferritin, ng/mL                51 (26--90)         64 (29--122)        0.001
  TSH, µIU/mL                    1.5 (0.9--2.7)      1.4 (0.9--2.2)      0.308

NT-proBNP - N-terminal pro B-type natriuretic peptide; TSH - thyrotropin-stimulating hormone

###### 

Two-dimensional transthoracic echocardiographic, Doppler data

                                 Female (n=577)   Male (n=488)    *P* value
  ------------------------------ ---------------- --------------- -----------
  LVEF, %                        60 (53--62)      55 ( 47--60)    \<0.001
  e', cm/sn                      7 (6--8)         7 (6--8)        0.680
  E/e'                           10 (8--13)       9 (7--12)       \<0.001
  **LV diastolic dysfunction**                                    
   None                          71 (12.4)        70 (14.3)       0.042
   Grade 1                       132 (22.8)       57 (31.3)       
   Grade 2                       236 (40.9)       172 (35.3)      
   Grade 3                       138 (23.9)       93 (19.1)       
  LVED dimension, mm             48 (44--51)      49 (45--54)     \<0.001
  LVES dimension, mm             32 (29--36)      33 (30--39)     \<0.001
  IVS dimension, mm              11 (10--12)      12 (10--13)     0.007
  LVPW dimension, mm             10 (10--11)      11 (10--12)     0.008
  LAVI, mL/m^2^                  35 (30--41)      33 (29--41)     0.067
  LA enlargement                 300 (52.0)       224 (45.9)      0.063
  LVMI, g/m^2^                   108 (90--128)    110 (90--130)   0.323
  LV concentric hypertrophy      386 (66.9)       221 (45.3)      \<0.001
  PAPs, mm Hg                    30 (17--38)      27 (15--35)     \<0.001
  **Mitral regurgitation**                                        
   None                          149 (25.8)       156 (32.0)      0.003
   Mild                          289 (50.1)       257 (52.7)      
   Moderate                      135 (23.4)       74 (15.2)       
   Severe                        4 (0.7)          1 (0.2)         
  **Mitral stenosis**                                             
   None                          547 (95.0)       480 (98.4)      0.010
   Mild                          19 (3.3)         6 (1.2)         
   Moderate                      10 (1.7)         2 (0.4)         
  **Aortic stenosis**                                             
   None                          554 (96.2)       475 (97.3)      0.533
   Mild                          15 (2.6)         8 (1.6)         
   Moderate                      7 (1.2)          5 (1.0)         
  **Aortic regurgitation**                                        
   None                          420 (72.9)       386 (79.1)      0.064
   Mild                          137 (23.8)       90 (18.4)       
   Moderate                      19 (3.3)         12 (2.5)        
  **Tricuspid regurgitation**                                     
   None                          190 (32.9)       196 (40.2)      0.003
   Mild                          238 (41.2)       208 (42.6)      
   Moderate                      123 (21.3)       73 (15.0)       
   Severe                        26 (4.5)         11 (2.3)        

IVS - interventricular septum; LA - left atrium; LAVI - left atrial volume index; LV - left ventricle; LVED - left ventricular end-diastolic; LVEF - left ventricle ejection fraction; LVES - left ventricular end-systolic; LVMI - left ventricular mass index; LVPW - left ventricular posterior wall; PAPs - pulmonary artery systolic pressure

Compared with female patients, male patients had significantly higher interventricular septum thickness, left ventricular posterior wall thickness, left ventricular end-diastolic and end-systolic dimensions, whereas LVEF was lower (55% vs. 60%, p\<0.001) in men. Women had worse diastolic function \[E/e'=10 (range:8--13) vs. 9 (range:7--12), p\<0.001\], and they were associated with a trend toward higher prevalence of abnormal left ventricular geometry (concentric hypertrophy or eccentric hypertrophy, or concentric remodeling) and higher pulmonary artery systolic pressure compared with those in men. Women also had higher prevalence of mitral and tricuspid valvular regurgitation compared with what men had.

Beta-blockers, statins, and antiplatelets were less frequently prescribed to women. Women more often received angiotensin receptor blockers, non-dihydropyridine and dihydropyridine calcium blockers, anticoagulants, and thiazide diuretics as compared with their male counterparts ([Table 4](#T4){ref-type="table"}). The use of other medications was similar in the two groups.

###### 

Medications

                                             Female (n=577)   Male (n=488)   *P* value
  ------------------------------------------ ---------------- -------------- -----------
  Angiotensin-converting enzyme inhibitors   179 (31.0)       175 (35.9)     0.095
  Angiotensin receptor blockers              173 (30.0)       119 (24.4)     0.041
  Beta-blockers                              318 (55.1)       306 (62.7)     0.012
  Aldosterone antagonists                    92 (15.9)        87 (17.8)      0.413
  Ivabradine                                 3 (0.5)          7 (1.4)        0.200
  Amiodarone                                 12 (2.1)         8 (1.6)        0.656
  Propafenone                                3 (0.5)          0 (0)          0.255
  Non-dihydropyridine calcium blockers       80 (13.9)        38 (7.8)       0.002
  Dihydropyridine calcium blockers           133 (23.1)       80 (16.4)      0.007
  Digoxin                                    31 (5.4)         37 (7.6)       0.166
  Statins                                    110 (19.1)       168 (34.4)     \<0.001
  Loop diuretics                             202 (35.0)       146 (29.9)     0.078
  Thiazide                                   194 (33.6)       124 (25.4)     0.004
  Isosorbide                                 19 (3.3)         29 (5.9)       0.038
  Antiaggregant                              210 (36.4)       269 (55.1)     \<0.001
  Anticoagulant                              185 (32.1)       110 (22.5)     0.001
  Non-steroidal anti-inflammatory drugs      47 (8.1)         31 (6.4)       0.263
  Oral antihyperglysemic                     142 (24.6)       104 (21.3)     0.203
  Insulin                                    50 (8.7)         37 (7.6)       0.575

Etiology of HF differed between both the sexes ([Table 5](#T5){ref-type="table"}). Female patients were more likely to have atrial fibrillation (32.4% vs. 22.1%, p\<0.001), hypertension (26.3% vs. 23.8%, p\<0.001), and valvular heart disease (14.6% vs. 7.4%, p\<0.001) as a cause of HF. However, ischemic heart disease (42.6% vs. 21.1%, p\<0.001) was the most common cause of HF in male patients.

###### 

Etiology of heart failure

                        Female (n=577)   Male (n=488)   *P* value
  --------------------- ---------------- -------------- -----------
  Ischemic              122 (21.1)       208 (42.6)     
  Atrial fibrillation   187 (32.4)       108 (22.1)     
  Hypertension          152 (26.3)       116 (23.8)     \<0.001
  Valvular disease      84 (14.6)        36(7.4)        
  Other                 32 (5.5)         20 (4.1)       

Comparison of female and male patients with HFpEF {#sec2-4}
-------------------------------------------------

[Table 6](#T6){ref-type="table"} shows the differences between the patients with HFpEF of different genders. Of the 819 patients with HFpEF, 473 (57.8%) were female. Compared with male patients, female had significantly higher body mass index. Prevalence of hypertension was higher in female patients with HFpEF; however, male had higher prevalence of coronary artery disease. The NT-proBNP levels were significantly higher in female than in male patients with HFpEF. Compared with men, LVEF, LAVI, and E/e' were higher in women with HFpEF. Etiology of HF was significantly different in female and male. The main etiology of HF was atrial fibrillation (33.8%) in female patients; however, the most common cause of HF was hypertension (30.1%) in male patients with HFpEF.

###### 

Heart failure with preserved ejection fraction in female and male

                                                       Female (n=473)      Male (n=346)        *P* value
  ---------------------------------------------------- ------------------- ------------------- -----------
  Age, years                                           67 (61--75)         67 (60--74)         0.262
  Smoking                                              29 (6.1)            100 (28.9)          \<0.001
  Alcohol use                                          26 (7.5)            3 (0.6)             \<0.001
  Body mass index, kg/m^2^                             29 (26--33)         27 (24--30)         \<0.001
  Heart rate, bpm                                      80 (70--92)         78 (70--90)         0.076
  History of hospitalization for HF in the last year   92 (19.5)           60 (17.3)           0.443
  **Comorbidities**                                                                            
   Atrial fibrillation                                 194 (41.0)          119 (34.4)          0.054
   Hypertension                                        377 (79.7)          246 (71.1)          0.004
   Diabetes mellitus                                   153 (32.3)          91 (26.3)           0.062
   Anemia                                              165 (34.9)          120 (34.6)          0.903
   Chronic kidney disease                              43 (9.1)            45 (13.0)           0.074
   Obstructive sleep apnea                             26 (5.5)            29 (8.4)            0.103
   Coronary artery disease                             116 (24.5)          155 (44.8)          \<0.001
   Previous myocardial infarction                      31 (6.6)            48 (13.9)           \<0.001
  **Laboratory data**                                                                          
   NT-proBNP, pg/mL                                    574 (263--1060)     483 (224--865)      0.021
   Blood urea nitrogen, mg/dL                          17 (13--22)         17 (13--22)         0.666
   Serum creatinine, mg/dL                             0.8 (0.7--1)        0.9 (0.8--1.1)      \<0.001
   Serum potassium, mmol/L                             4.6 (4.3--5.0)      4.5 (4.2--5.0)      0.817
   Haemoglobin, g/dL                                   12.7 (11.4--13.5)   13.8 (12.3--15.0)   \<0.001
   Ferritin, ng/mL                                     51 (25--88)         63 (28--132)        0.003
  **Echocardiography**                                                                         
   LVEF, %                                             60 (55--65)         59 (55--62)         \<0.001
   E/e'                                                9.8 (8.0--12.4)     9.0 (7.1--12.0)     0.002
   **LV diastolic dysfunction**                                                                
    None                                               57 (12.1)           47 (13.5)           0.054
    Grade 1                                            114 (24.1)          111 (32.1)          
    Grade 2                                            192 (40.6)          119 (34.5)          
    Grade 3                                            110 (23.2)          69 (19.9)           
   LVED dimension, mm                                  48 (44--51)         47 (44--52)         0.168
   LVES dimension, mm                                  31 (28--35)         32 (29--36)         0.033
   LAVI, mL/m^2^                                       35 (30--40)         33 (28--38)         0.029
  **Medications**                                                                              
   Angiotensin-converting enzyme inhibitors            151 (31.9)          114 (32.9)          0.757
   Angiotensin receptor blockers                       142 (30.0)          86 (24.9)           0.103
   Beta-blockers                                       246 (52.0)          206 (59.5)          0.032
   Aldosterone antagonists                             70 (14.8)           50 (14.5)           0.889
   Nondihydropyridine calcium blockers                 70 (14.8)           32 (9.2)            0.17
   Dihydropyridine calcium blockers                    112 (23.7)          67 (19.4)           0.140
   Digoxin                                             22 (4.7)            28 (8.1)            0.042
   Isosorbide                                          16 (3.4)            15 (4.3)            0.480
   Loop diuretics                                      157 (33.2)          93 (26.9)           0.053
   Thiazide                                            163 (34.5)          77 (22.3)           \<0.001
  **Etiology of heart failure**                                                                
   Ischemic                                            76 (16.1)           98 (28.3)           \<0.001
   Atrial fibrillation                                 160 (33.8)          96 (27.7)           
   Hypertension                                        142 (30.0)          104 (30.1)          
   Valvular disease                                    74 (15.6)           31 (9.0)            
   Other                                               21 (4.4)            17 (4.9)            

HF - heart failure; LAVI - left atrial volume index; LV - left ventricle; LVED - left ventricular end-diastolic; LVEF - left ventricle ejection fraction; LVES - left ventricular end-systolic; NT-proBNP - N-terminal pro B-type natriuretic peptide

Comparison of female and male patients with HFmrEF {#sec2-5}
--------------------------------------------------

Of the 246 patients with HFmrEF, 142 (57.7%) were male. Compared with women, men were younger, had significantly lower body mass index and heart rate. There were significantly more smokers and alcohol users among the men with HFmrEF. Women had higher prevalence of atrial fibrillation. On the other hand, prevalence of coronary artery disease was higher in male patients with HFmrEF. In female patients with HFmrEF, the NT-proBNP levels (1167 pg/mL vs. 677 pg/mL, p\<0.001) and E/e' value (10.1 vs. 9, p=0.009) were significantly higher, and hemoglobin levels were lower. Angiotensin-converting enzyme inhibitors were more frequently prescribed to men; however, women more often received dihydropyridine calcium blockers. The use of other medications was similar in the two groups. In patients with HFmrEF, ischemic heart disease was the most common cause of HF in both sexes ([Table 7](#T7){ref-type="table"}).

###### 

Heart failure with mid-range ejection fraction in female and male

                                                       Female (n=104)      Male (n=142)        *P* value
  ---------------------------------------------------- ------------------- ------------------- -----------
  Age, years                                           71 (62--79)         67 (62--74)         0.004
  Smoking                                              3 (2.9)             56 (39.4)           \<0.001
  Alcohol use                                          2 (1.9)             15 (10.6)           0.009
  Body mass index, kg/m^2^                             29 (27--32)         27 (25--31)         0.003
  Heart rate, bpm                                      83 (74--97)         76 (68--86)         \<0.001
  History of hospitalization for HF in the last year   31 (29.8)           38 (26.8)           0.599
  **Comorbidities**                                                                            
   Atrial fibrillation                                 41 (39.4)           27 (19.0)           \<0.001
   Hypertension                                        77 (74.0)           111 (78.2)          0.451
   Diabetes mellitus                                   31 (29.8)           44 (31.0)           0.843
   Anemia                                              39 (37.5)           48 (33.8)           0.173
   Chronic kidney disease                              16 (15.4)           28 (19.7)           0.381
   Obstructive sleep apnea                             4 (3.8)             2 (1.4)             0.245
   Coronary artery disease                             54 (51.9)           113 (79.6)          \<0.001
   Previous myocardial infarction                      38 (36.5)           80 (56.3)           0.002
  **Laboratory data**                                                                          
   NT-proBNP, pg/mL                                    1167 (592--2114)    677 (368--1305)     \<0.001
   Blood urea nitrogen, mg/dL                          19.5 (15--27.7)     17.0 (14.0--22.2)   0.028
   Serum creatinine, mg/dL                             0.8 (0.7--1.1)      0.9 (0.8--1.1)      \<0.001
   Serum potassium, mmol/L                             4.6 (4.3--4.9)      4.6 (4.3--4.9)      0.886
   Haemoglobin, g/dL                                   12.6 (11.4--13.6)   13.8 (12.4--15.0)   \<0.001
   Ferritin, ng/mL                                     62 (27--99)         66 (34--112)        0.393
  **Echocardiography**                                                                         
   LVEF, %                                             45 (41--45)         45 (40--45)         0.461
   E/e'                                                10.1 (8.1--13.1)    9.0 (7.0--11.4)     0.009
   **LV diastolic dysfunction**                                                                
    None                                               14 (13.4)           23 (16.3)           0.032
    Grade 1                                            18 (17.4)           42 (29.5)           
    Grade 2                                            44 (42.3)           53 (37.3)           
    Grade 3                                            28 (26.9)           24 (16.9)           
   LVED dimension, mm                                  50.5 (45.0--53.7)   53.0 (49.0--57.0)   0.001
   LVES dimension, mm                                  35.0 (30.2--41.0)   39.0 (33.0--45.0)   0.005
   LAVI, mL/m^2^                                       35 (31--42)         35 (30--43)         0.592
  **Medications**                                                                              
   Angiotensin-converting enzyme inhibitors            28 (26.9)           61 (43.0)           0.010
   Angiotensin receptor blockers                       31 (29.8)           33 (23.2)           0.246
   Beta-blockers                                       72 (69.2)           100 (70.4)          0.840
   Aldosterone antagonists                             22 (21.2)           37 (26.1)           0.374
   Nondihydropyridine calcium blockers                 10 (9.6)            6 (4.2)             0.090
   Dihydropyridine calcium blockers                    21 (20.2)           13 (9.2)            0.013
   Digoxin                                             9 (8.7)             9 (6.3)             0.491
   Isosorbide                                          3 (2.9)             14 (9.9)            0.041
   Loop diuretics                                      45 (43.3)           53 (37.3)           0.347
   Thiazide                                            31 (29.8)           47 (33.1)           0.584
  **Etiology of heart failure**                                                                
   Ischemic                                            46 (44.2)           110 (77.5)          \<0.001
   Atrial fibrillation                                 27 (26.0)           12 (8.5)            
   Hypertension                                        10 (9.6)            12 (8.5)            
   Valvular disease                                    10 (9.6)            5 (3.5)             
   Other                                               11 (10.6)           3 (2.1)             

HF - heart failure; LAVI - left atrial volume index; LV - left ventricle; LVED - left ventricular end-diastolic; LVEF - left ventricle ejection fraction; LVES - left ventricular end-systolic; NT-proBNP - N-terminal pro B-type natriuretic peptid

Age distribution by gender in patients with HFmrEF and HFpEF {#sec2-6}
------------------------------------------------------------

Mean age of our HFpEF cohort was 67 years, with almost 50% of the patients aged between 65 and 80 years. Temporal trend analysis showed female predominance among all age groups in patients with HFpEF ([Fig. 1](#F1){ref-type="fig"}). On the other hand, mean age of patients with HFmrEF was 68 years, with \>50% of the patients aged between 65 and 80 years. This analysis revealed male predominance among those aged \<80 years in patients with HFmrEF, whereas, in older patients, percentage of females increased, and ultimately the rate of female exceeded the male ratio in HFmrEF group ([Fig. 2](#F2){ref-type="fig"}).

![Age distribution by gender in patients with heart failure and preserved ejection fraction. Number of patients (a), proportion of patients (b). Temporal trend analysis showed female predominance among all age groups\
HFpEF - heart failure with preserved ejection fraction](AJC-21-242-g001){#F1}

![Age distribution by gender in patients with heart failure and mid-range ejection fraction. Number of patients (a), proportion of patients (b). The proportion of males among patients aged \<80 years was higher than that of females; whereas in the elderly, the proportion of females was higher\
HFmrEF - heart failure with mid-range ejection fraction](AJC-21-242-g002){#F2}

Discussion {#sec1-4}
==========

Previous epidemiological studies revealed a female predominance in the development of HFpEF ([@ref17]). Fifty-five percent of patients with HFpEF were female in the Swedish Heart Failure Registry, which included over 18,000 patients with HFpEF and HFmrEF ([@ref18]). However, most of these studies were clinical drug trials, and they may not reflect real-life patients with HFpEF. Moreover, to the best of our knowledge, there have been no studies evaluating gender differences in patients with HFmrEF.

In this analysis from APOLLON study, we evaluated sex differences in demographic, clinical, and laboratory parameters in a large national cohort of patients with HFmrEF and HFpEF in a real-world setting. Our results indicate that the clinical manifestations of HFmrEF and HFpEF differ widely between women and men. Women were usually older at presentation, and had a greater burden of atrial fibrillation and hypertension; on the other hand, men were more likely to have coronary and peripheral artery disease, hyperlipidemia, and malignancy compared with women. Our results also showed that signs and symptoms may also have sex-related differences: women tended to be more symptomatic for palpitations, reduced exercise tolerance, peripheral edema, and fatigue on admission. The ratio of HFmrEF was also significantly different among men and women; nearly one-fifth of the women and one-third of the men had HFmrEF in our study cohort. Another important difference concerns the management of HF; men were more likely to receive beta-blockers, statins, and antiplatelets, probably due to higher prevalence of ischemic heart disease in men, whereas women more often received anticoagulant drugs that may be secondary to the higher prevalence of atrial fibrillation in women.

Over the past decade, one of the most important findings across numerous HFpEF studies was a distinct gender distribution. Generally, women significantly outnumber men, leading to a gender ratio of approximately 2:1 in HFpEF ([@ref19], [@ref20]). In our study, 57.8% of the patients with HFpEF were female. Previous studies have shown that women with HFpEF tend toward higher LVEF, less often active or former smokers, had worse diastolic function and less comorbid conditions as compared with men ([@ref20], [@ref21]). In line with these data, in our cohort, women were less often active or former smokers, had higher LVEF, had worse diastolic function, and had higher prevalence of hypertension and atrial fibrillation. Deswal and Bozkurt ([@ref10]) analyzed 719 patients with HFpEF and found that compared with men, women with HFpEF were older and more frequently had a history of diabetes or hypertension, history of myocardial infarctions, and ischemic causes of HF were less frequent in women than in men. At the time of enrollment, women appeared to have greater clinical severity of HF, as evidenced by more women with New York Heart Association (NYHA) class III or IV and fewer women with NYHA class I functional status, a greater proportion of women with a history of orthopnea and resting dyspnea, chest X-ray findings of vascular congestion, and examination findings of rales and edema, as well as more women receiving diuretics ([@ref10]). Similar to the previous data, the APOLLON study showed that female patients with HFpEF were more symptomatic (palpitations, reduced exercise tolerance, peripheral edema, and fatigue), and they more often received diuretics on admission. In the APOLLON study, ischemic heart disease and ischemic etiology of HF were less frequent in females than in males with HFpEF. Recent findings from studies investigating HFpEF pathophysiology, mechanisms, and sex effects on cardiovascular aging have identified some potential contributors to the sex discrepancy ([@ref22], [@ref23]). Extent of concentric ventricular remodeling is enhanced in women, and this may be associated with worse diastolic function in the aged female heart ([@ref24]). In our study, although LVEF was higher in women with HFpEF, women were more symptomatic and had higher NT-proBNP levels compared with men probably due to worse diastolic function, higher LAVI and pulmonary artery systolic pressure, and more frequent LV concentric hypertrophy.

The 2016 European Society of Cardiology HF guidelines recognized HFmrEF as an entity distinct from HFrEF and HFpEF ([@ref2]). Clinical characteristics of HFmrEF were found to be intermediate between those of HFrEF and HFpEF ([@ref25]). Some authors suggest that HFmrEF has a phenotype closer to HFpEF ([@ref13]), whereas other authors consider it closer to HFrEF ([@ref26]). Recent studies have shown that patients with HFmrEF were younger, more often male, and had more frequent ischemic heart disease compared with HFpEF ([@ref27]). Even though patients with HFmrEF have higher readmission rates than patients with HFpEF and mortality rates comparable to HFrEF and HFpEF ([@ref28]), HFmrEF remains insufficiently characterized compared with the other groups. In addition, there are limited data regarding the effect of gender in patients with HFmrEF. Swedish Heart Failure Registry included 9019 patients with HFmrEF, and 60.8% of these patients were male ([@ref18]). Kapoor et al. ([@ref29]) analyzed the factors potentially contributing to the HF hospitalization among 99,825 HF admissions from 305 hospitals in the Get With The Guidelines-HF (GWTG-HF) database; and among the 12,819 patients with HFmrEF, 51.5% were male. The APOLLON study has shown that prevalence of male was 57.7% in patients with HFmrEF. Previous studies revealed that there might be differences in sex distribution by age in patients with HF ([@ref30]). Stein et al. ([@ref31]) studied all consecutive 5228 males and 4107 females hospitalized patients with HF, aged 50 or older. Although there was no separate evaluation for HFmrEF and HFpEF in this study, the proportion of males among patients aged \<75 years was significantly higher than that of females, whereas in the elderly the proportion was similar in both genders ([@ref31]). We analyzed gender distribution by age groups for HFmrEF and HFpEF groups. In our study, female gender was higher among all age groups in patients with HFpEF. However, male gender was higher in patients with HFmrEF aged \<80 years, and female gender was higher in octogenarian patients with HFmrEF. In patients with HFmrEF, men smoked more, and were younger, had higher prevalence of coronary artery disease, had lower prevalence of atrial fibrillation, had better diastolic function, and had lower NT-proBNP levels. Ischemic heart disease was the main cause of HF in men and women with HFmrEF.

This study provides contemporary data on gender differences in clinical features and management of patients with HFmrEF and HFpEF who participated in the APOLLON study. Several baseline clinical and echocardiographic features were found to differ significantly between women and men. Female subjects were older compared with males. There were gender differences in comorbidity status. Some were as expected, for example, coronary artery disease, and hyperlipidemia were more common among men, and hypertension and atrial fibrillation disease were more common in women. Our study also showed that gender discrepancies in HFmrEF and HFpEF management may exist in our country. The presence of this gender difference in the epidemiology and management of HFmrEF and HFpEF should be investigated in prospective studies to reveal whether these differences have consequences for outcome. Therefore, we need prospective clinical trials evaluating the management and prognosis of HFmrEF and HFpEF in both sexes throughout the country.

Study limitations {#sec2-7}
-----------------

This study is a post-hoc analysis of the APOLLON registry. The main limitations of this study are its observational nature and lack of follow-up data. We assessed the associations between gender and HFmrEF or HFpEF, but we cannot demonstrate causality. The limitation of the "clinician-judged HF" diagnosis in the APOLLON registry is also acknowledged. Another limitation is that the coverage of the study is limited to outpatient cardiology clinics; hospitalized patients are not included in this study.

Conclusion {#sec1-5}
==========

In this large real-world survey, we demonstrated that clinical manifestations of HFmrEF and HFpEF differed widely between women and men. Patients with HFpEF are predominantly women, and patients with HFmrEF are predominantly men. Female patients with HFpEF are more symptomatic, have higher body mass index, have higher NT-proBNP levels, have worse diastolic function, and have higher prevalence of hypertension. The main etiology of HF is atrial fibrillation in these patients. Male patients with HFmrEF are younger, have higher prevalence of coronary artery disease, have more dilated left ventricle, and have better diastolic function. To the best of our knowledge, this is the first study to analyze gender differences in patients with HFmrEF. The results of this multicenter study have presented a broad perspective on gender in patients with HFmrEF and HFpEF in Turkey.
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